Zacks small cap research.

1. Source: Created by Zacks Small Cap Research Analysts. By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT BALANCE Interim Results On June 2, 2021, Protalix and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX …5 Small Cap Value Stocks to Keep on Your Watch List. 1. Caleres (. CAL Quick Quote. CAL - Free Report) is a specialty retailer with over 1000 retail locations in 68 countries. Its brands include ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …What's a "thinking cap" -- and could it make me a genius? It's doubtful, but this technology could help you. Learn more about the thinking cap here. Advertisement ­You couldn't have graduated from elementary school without a teacher instruc...

Mar 31, 2023 · In 4Q22, Novonix Anode Materials was selected to enter negotiations to receive US$150 million in grant funding from the Department of Energy (DOE) to expand its domestic synthetic graphite anode materials production, which we view as a positive. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you ... ORMP: Data from NASH Phase 2 Study – Positive Takeaways . 11/21/2022. Download (opens in new window)The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ...

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Phase 2b Data for EB01 in January 2023 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a double blind, placebo controlled trial to evaluate the safety and efficacy of 2.0% EB01 cream in approximately 170 evaluable subjects in …By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO-MUC5AC, which are the company’s investigational candidates designed as potential treatments

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.Research Reports. Companies by Analyst. Steven Ralston, CFA; David Bautz, PhD; Ann Heffron, CFA, CPA; Thomas Kerr, CFA; Brian Lantier, CFA; M. Marin; Brad Sorensen, …“Yes! Success!” “Yes! Success!” It wasn’t quite “Mr. Watson. Come Here. I need you.” but it could prove to be just as revolutionary: Researchers at the University of Washington have completed the first experiment demonstrating human brain-t...© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)

About Zacks Small-Cap Research Zacks/SCR prepares company-sponsored, independent research and related content for distribution through a multitude of investor and media channels, both traditional ...

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By Ann Heffron, CFA, CPA OTC:CPKF READ THE FULL CPKF RESEARCH REPORT Chesapeake Financial’s (OTC:CPKF) third quarter net earnings increased $0.5 million, or 13%, year over year to $4.2 million, while 2022’s third quarter diluted EPS rose by $0.12, or 15%, to $0.90 from $0.78 posted a year ago. Results exclude a one-time gain …ZACKS SMALL/MID CAP ETF. The Zacks Small/Mid Cap ETF seeks to generate consistent and sustainable returns while minimizing the risk of capital …23 Nov 2020 ... We are initiating coverage of Mateon Therapeutics,. Inc. (MATN) with a $0.40 valuation. Mateon is a biopharmaceutical company focused on the.Giles Haycock Managing Director (T) 312.265.9351 (M) 312.752.6718 (F) 312.265.9560 (E) [email protected] Twitter: @ZacksSmallCap Steven Ralston, CFA Director of Research

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT First Quarter 2022 Results On May 16, 2022, Novan Inc. (NASDAQ: ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information …Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research. BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain …By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO …How many stars would you give Zacks Investment Research? Join the 86 people who've already contributed. Your experience matters.By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Third Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 3Q:23 results on November 13, 2023 via its filing of Form 10-Q with the SEC. Since the filing of the second quarter 10-Q in mid-August, the company has finished compiling and submitting its investigational new drug (IND)

Thomas Kerr, CFA is a Senior Equity Research Analyst with Zacks Small-Cap Research, with over 25 years of securities industry experience in Technology, Consumer, Industrials, Med-Tech, Healthcare & Biotechnology sectors. Prior to joining Zacks in 2021, Tom was Senior Investment Specialist at WestPac Wealth Partners, Chief Investment Officer ...

Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. _____ 1. BioLineRx Corporate Website, Accessed September 2023.RVLP: Bright-Eyed and Bushy-Tailed. 04/10/2023. By John Vandermosten, CFA. NASDAQ:RVLP. The Journal of Plastic, Reconstructive and Aesthetic Surgery published an article entitled The Effect of Topical Oxymetazoline on Eyelid Position, Eye Redness, and Patient-Reported Eye Appearance: A Randomized Controlled Trial.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Premium Research for ZSCCX. Zacks MF Rank. More Info. This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Fund's over the next 6 months: Zacks Rank ...By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 knows the company well, in our view.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window) By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update First Patient Dosed in Phase 1b/2 Trial for Exebacase in Chronic Knee Prosthetic Joint Infections On April 26, 2023, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 1b/2 clinical trial of exebacase …We run some scenario analyses to evaluate the total cost of an entity acquiring Tenax. If an acquiror’s bid price was set at $1.00 per share, the estimated cost to acquire the company would be approximately $52 million. At $2.00 per share, the price increases to $131 million and at $3.00, $210 million. See exhibit below for details on the ...

1. Source: Created by Zacks Small Cap Research Analysts. By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT BALANCE Interim Results On June 2, 2021, Protalix and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX …

By M. Marin NASDAQ:NVX | OTC:NVNXF READ THE FULL NVX RESEARCH REPORT Company positioning to benefit from ramping growth in target verticals Novonix (NASDAQ:NVX) (OTC:NVNXF) has a positive sector tailwind, in our opinion, as it advances its strategy to develop a U.S.-based lithium-ion battery materials …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Jan 13, 2023 · By Lisa Thompson OTC:NEXCF READ THE FULL NEXCF RESEARCH REPORT Yesterday Nextech (OTC:NEXCF) preannounced preliminary 2022 revenues of $10.3 million for the year or $1.4 million for Q4 2022. While this looks like a miss compared to our model, it includes $958,822 in revenues eliminated from historical product sales booked in Q1 and Q2 due to reclassifying the pet business as a discontinued By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT First Quarter 2022 Results On May 16, 2022, Novan Inc. (NASDAQ: ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information …Earnings Update. • Cash and cash equivalents were $1.5 million at the end of 3Q, down from $3.8 million at the end of 1Q. o During 3Q, Ensysce (NASDAQ:ENSC) completed a convertible note financing offer that netted the company roughly $560,000 before fees and offering expenses, with the potential for another $1.13 million upon “satisfaction ...© Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)When you start getting deeper into the world of investing, you’ll begin learning an entirely new, finance-specific vocabulary. From assets and mutual funds to expense ratios and the New York Stock Exchange, there’s certainly a lot to absorb...By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, ...By John Vandermosten, CFA. NASDAQ:RVPH. READ THE FULL RVPH RESEARCH REPORT. 2Q:23 Financial and Operational Results. On August 15, 2023, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported 2Q:23 financial and operational results and filed its Form 10-Q with the SEC. Since our previous update in …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, ...Instagram:https://instagram. super cheap renters insurancevalue of a kennedy silver dollarchatgpt stock price todaywatson x ai By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update First Patient Dosed in Phase 1b/2 Trial for Exebacase in Chronic Knee Prosthetic Joint Infections On April 26, 2023, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 1b/2 clinical trial of exebacase …SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting … benz amg gle 63gas and oil stocks INX (OTC:INXDF) announced that Republic Group, described as “a global financial firm operating a digital merchant bank and a network of investment platforms,” is investing $5.25 million into the company in exchange for approximately 9.5% of outstanding shares. The deal, according to INX, values INX at approximately $50 million before the ...Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers. fractional property investment Zacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street. Our analysts seek to identify and report...Zacks Premium Research for ZSCCX View All Zacks Mutual Fund Rank #1's View the Zacks Mutual Fund Rank Guide Annual Return * 1 = Top 20%, 5 = Bottom 20% …Yes, absolutely. Zacks is worth it. Given that the stocks they rate as a #1 Strong Buy have beat the SP500 by 13.9% on average for the last 34 years, their system works. And the fact that the stocks they rate as a #5 Strong Sell have underperformed the market by 8.4% all but proves their system.